

Vaccine Pipeline Tracking- This document is meant to serve as a guideline. It may not represent/include every vaccine in the manufacturers pipelines. This document is up to date as of April 2026

Company	Disease Area	Product Type	Product Name	Trial Phase	Target Population	PDUFA Date	Notes	Sources
Ab&B Bio-tech Co., Ltd.JS	Rabies	Vaccine		Phase 3	Adults 18-60 years of age			https://clinicaltrials.gov/study/NCT07275645?intr=Vaccine&aggFilters=status:not%20rec&page=39&rank=381
Ab&B biotech	Herpes Zoster	Vaccine		Phase 1/2	Adults aged 40 years and older			https://clinicaltrials.gov/study/NCT06851832?intr=Vaccine&aggFilters=status:not%20rec&page=13&rank=129
Aimei Vacin Biopharm	meningitis	Vaccine		Phase 2	3 months-15 years			https://clinicaltrials.gov/study/NCT06337071?intr=Vaccine&aggFilters=status:not%20rec&page=14&rank=136
Aimei Vacin Biopharm	Pneumococcal	Vaccine		Phase 3	2+ year olds		23-valent	https://clinicaltrials.gov/study/NCT06044077?intr=Vaccine&aggFilters=status:not%20rec&page=14&rank=131
Astrazeneca	C-dif	Vaccine	AZD5148	Phase 1			reduction in recurrence	https://www.astrazeneca.com/our-therapy-areas/pipeline.html#vi
Astrazeneca	COVID-19	mRNA vaccine	mRNA VLP	Phase 1				https://www.astrazeneca.com/our-therapy-areas/pipeline.html#vi
Astrazeneca	COVID-19	Vaccine	Kavigale SUPERNOVA	Phase 3				https://www.astrazeneca.com/our-therapy-areas/pipeline.html#vi
Astrazeneca	Non-CF bronchiectasis	Vaccine	AZD0292	Phase 1				https://www.astrazeneca.com/our-therapy-areas/pipeline.html#vi
Astrazeneca	Staph aureus infection	Vaccine	AZD7760	Phase 2				https://www.astrazeneca.com/our-therapy-areas/pipeline.html#vi
Bavarian Nordic	Equine encephalitis	Vaccine	MVA-BN WEV	Phase 2	healthy adults		Started in partnership with DoD	https://www.bavarian-nordic.com/what-we-do/pipeline/equine-encephalitis.aspx

Beijing Luzhu Biotechnology Co., Ltd.	Herpes Zoster	Vaccine	LZ901	Phase 3	healthy adults 40 years and older		https://clinicaltrials.gov/study/NCT06088745?intr=Vaccine&aggFilters=status:not%20rec&page=19&rank=189
Beijing Minhai Biotechnology Co., Ltd	Pneumococcal	Vaccine		Phase 3	children 12-15 months of age	13-valent	https://clinicaltrials.gov/study/NCT06608199?intr=Vaccine&aggFilters=status:not%20rec&page=53&rank=522
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	DTaP	Vaccine		Phase 3	3 month old infants		https://clinicaltrials.gov/study/NCT06344065?intr=Vaccine&aggFilters=status:not%20rec&page=29&rank=290
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Group B meningococcal E coli	Vaccine		Phase 1	6 months-50 years		https://clinicaltrials.gov/study/NCT06314880?intr=Vaccine&aggFilters=status:not%20rec&page=44&rank=435
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Pneumococcal	Vaccine		Phase 3	2-3 month old children	15-valent	https://clinicaltrials.gov/study/NCT04357522?intr=Vaccine&aggFilters=status:not%20rec&page=20&rank=191
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Shigella	Vaccine		Phase 3	Children 6 months-5 years		https://clinicaltrials.gov/study/NCT06838195?intr=Vaccine&aggFilters=status:not%20rec&page=36&rank=353
BioNTech SE	COVID-19	Vaccine		Phase 3	Children 5-11 at higher risk of severe COVID		https://clinicaltrials.gov/study/NCT07222384?intr=Vaccine&aggFilters=status:not%20rec&page=41&rank=404
Butantan Institute	Dengue	Vaccine		Phase 3	40-59 year olds and 60- 79 year olds		https://clinicaltrials.gov/study/NCT06891950?intr=Vaccine&aggFilters=status:not%20rec&page=14&rank=132

Butantan Institute	Influenza	Vaccine		Phase 1/2	Older adults	https://clinicaltrials.gov/study/NCT06842173?intr=Vaccine&aggFilters=status:not%20rec&page=13&rank=130
CanSino Biologics Inc.	Tuberculosis	Vaccine	Ad5-105K	Phase 1	Adults 18-45 years old	https://clinicaltrials.gov/study/NCT06732583?intr=Vaccine&aggFilters=status:not%20rec&page=30&rank=294
Centers for Disease Control and Prevention	Rotavirus	Microneedle Patch		Phase 1	Healthy adults aged 18-45 years old	https://clinicaltrials.gov/study/NCT06962904?intr=Vaccine&aggFilters=status:not%20rec&page=39&rank=386
CSL	Influenza	mRNA vaccine	CSL400	Phase 1		https://www.csl.com/research-and-development/product-pipeline
CSL	Pandemic influenza	Vaccine	CSL404	Phase 1		https://www.csl.com/research-and-development/product-pipeline
CSL	Pandemic influenza	Vaccine	CSL405	Phase 1		https://www.csl.com/research-and-development/product-pipeline
CSL	Pandemic influenza	mRNA vaccine	CSL406	Phase 1		https://www.csl.com/research-and-development/product-pipeline
CSPC Megalith Biopharmaceutical Co.,Ltd.	Herpes Zoster	Vaccine	SYS6017	Phase 1	Adults 40+ years old	https://clinicaltrials.gov/study/NCT06954818?intr=Vaccine&aggFilters=status:not%20rec&page=31&rank=308
Dynavax	H5N1	Vaccine	CpG1018	Phase 2		https://www.dynavax.com/pipeline/
Dynavax	Hep B	Vaccine	HEPLISAV-B	BLA Review	Adults on hemodialysis	https://www.dynavax.com/pipeline/
Dynavax	Lyme Disease	Vaccine	CPG1018	IND enabling		https://www.dynavax.com/pipeline/

							https://www.dynavax.com/pipeline/
Dynavax	Plague	Vaccine	CpG 1018	Phase 2	Adults 18-55	In partnership with DoD; Completed but still listed in pipeline on website	https://clinicaltrials.gov/study/NCT05506969#study-plan
							https://www.dynavax.com/pipeline/
Dynavax	shingles	Vaccine	Z-1018	Phase 2	Adults 50+	Recruiting	https://clinicaltrials.gov/study/NCT06569823#study-overview
							https://www.emergentbiosolutions.com/products-services/pipeline/
Emergent Biosolutions	Equine encephalitis	Vaccine	WEVEE VLP	Phase 1			https://www.emergentbiosolutions.com/products-services/pipeline/
							https://www.emergentbiosolutions.com/products-services/pipeline/
Emergent Biosolutions	Pan-Ebola	mAb		Pre-Clinical			https://clinicaltrials.gov/study/NCT07204457?intr=Vaccine&aggFilters=status:not%20rec&page=33&rank=321#study-overview
EyeGene Inc.	meningitis	Vaccine		Phase 2/3	19-55 year olds	Meningococcal (groups A, C, W-135, and Y)	https://clinicaltrials.gov/study/NCT07085702
						Phase 2 complete, still posted in pipeline on GSK website	https://clinicaltrials.gov/study/NCT05960097
GSK	COVID	mRNA vaccine	GSK4396687	Phase 2	healthy adults		https://clinicaltrials.gov/study/NCT07085702
GSK	Group A streptococcus pyogenes	Vaccine	GSK4424989	Phase 1	adults 18-25	Recruiting	https://clinicaltrials.gov/study/NCT05446740
						Phase 1 study complete, still posted in pipeline on GSK website	https://www.clinicaltrials.gov/study/NCT05446740
GSK	Influenza	mRNA vaccine	GSK4382276	Phase 1	healthy adults 18-55 and 65+		https://clinicaltrials.gov/study/NCT05480800
						Phase 1/2a complete, still posted in pipeline on GSK website	https://clinicaltrials.gov/study/NCT07036159?intr=Vaccine&aggFilters=status:not%20rec&page=16&rank=153
GSK	iNTS (Invasive nontyphoidal salmonella prophylaxis)	Vaccine	GSK4077164	Phase 1/2	adults 18-50 years of age		https://clinicaltrials.gov/study/NCT07036159?intr=Vaccine&aggFilters=status:not%20rec&page=16&rank=153
							https://clinicaltrials.gov/study/NCT07036159?intr=Vaccine&aggFilters=status:not%20rec&page=16&rank=153
GSK	Malaria	Vaccine		Phase 2	children 5-60 months in endemic areas		https://clinicaltrials.gov/study/NCT07036159?intr=Vaccine&aggFilters=status:not%20rec&page=16&rank=153

GSK	Measles, Mumps, Rubella, Varicella New Seed	Vaccine	GSK4406371	Phase 2	Children 4-6 years old	Phase 2 study complete, still posted in pipeline on GSK website	https://clinicaltrials.gov/study/NCT05630846
GSK	Meningococcal Group B	Vaccine	GSK3536829	Phase 3	healthy infants 6 weeks-12 weeks of age	Phase 3 complete, but still listed in pipeline on GSK website	https://www.clinicaltrials.gov/study/NCT03621670
GSK	Pneumococcal	Vaccine	Pn-MAPS30plus	Phase 1	adults 50-64 years of age		https://clinicaltrials.gov/study/NCT07105722?intr=Vaccine&aggFilters=status:not%20rec&page=53&rank=521
GSK	Pneumococcal 24-valent	Vaccine	GSK5101955	Phase 1	Children 12-15 months of age	Phase 1 study complete, still posted in pipeline on GSK website	https://clinicaltrials.gov/study/NCT04525599
GSK	Pneumococcal 24-valent	Vaccine	GSK5101955	Phase 2	healthy infants 6 weeks-12 weeks of age	Phase 2	https://www.clinicaltrials.gov/study/NCT05412030
GSK	RSV	Vaccine	RSVPreF3 0A	Phase 3b	Adults 18-49 at increased risk of severe RSV	Phase 3b complete, still posted in pipeline on GSK website	https://clinicaltrials.gov/study/NCT06389487
GSK	Seasonal Flu/COVID-19	mRNA vaccine	GSK547512	Phase 1/2	adults 18+ years old	Phase 1/2 complete, but still posted in pipeline on GSK website	https://clinicaltrials.gov/study/NCT06680375
GSK	Strep A	Vaccine		Phase 1	Adults 18-25 years of age		https://clinicaltrials.gov/study/NCT07085702?intr=Vaccine&aggFilters=status:not%20rec&page=50&rank=499
GSK	Uropathogenic escherichia coli (UTI vaccine)	Vaccine	GSK51032188	Phase 1/2	adults 18-64	Recruiting	https://clinicaltrials.gov/study/NCT06702449

							https://clinicaltrials.gov/study/NCT05084508 https://clinicaltrials.gov/study/NCT06693895?intr=Vaccine&aggFilters=status:not%20rec&page=5&rank=41
GSK	Varicella new seed	Vaccine	GSK4178116	Phase 2	children 12-15 months of age	Phase 2 complete, still posted in pipeline on GSK website	https://clinicaltrials.gov/study/NCT06855160?intr=Vaccine&aggFilters=status:not%20rec&page=2&rank=19
GSK	Varicella new seed	Vaccine	GSK4178116	Phase 3	healthy children 12-15 months of age	Recruiting	https://www.clinicaltrials.gov/study/NCT06806137
GSK	RSV	Vaccine	RSVPreF3 0A	Phase 2b	Adults 18-50 with lung or kidney transplant	Phase 2b complete, still posted in pipeline on GSK website	https://clinicaltrials.gov/study/NCT05921903
Institute for Molecular Medicine	Alzheimers	Vaccine	AV-1980R	Phase 1	adults aged 65-80 with biomarker evidence of early Alzheimer's disease		https://clinicaltrials.gov/study/NCT07158905?intr=Vaccine&aggFilters=status:not%20rec&page=50&rank=497
Institute of Medical Biology, Chinese Academy of Medical Sciences	Diphtheria, Tetanus, Pertussis	Vaccine		Phase 1	2 months-6 years of age		https://clinicaltrials.gov/study/NCT06184542?intr=Vaccine&aggFilters=status:not%20rec&page=52&rank=520
Institute of Medical Biology, Chinese Academy of Medical Sciences	Influenza	Vaccine		Phase 3	People 3+ years of age		https://clinicaltrials.gov/study/NCT06800950?intr=Vaccine&aggFilters=status:not%20rec&page=52&rank=512
Institute of Medical Biology, Chinese Academy of Medical Sciences	Rotavirus	Vaccine		Phase 2	Children aged 2-71 months		https://clinicaltrials.gov/study/NCT06080906?intr=Vaccine&aggFilters=status:not%20rec&page=48&rank=474

LG Chem	DTaP-HepB-IPV-Hib	Vaccine	LR20062	Phase 2	Infants 2-6 months old	https://clinicaltrials.gov/study/NCT06618196?intr=Vaccine&aggFilters=status:not%20rec&page=31&rank=302
LimmaTech Biologics	Shigella	Vaccine		Phase 2	Adults	https://clinicaltrials.gov/study/NCT06615375?intr=Vaccine&aggFilters=status:not%20rec&page=63&rank=629
LimmaTech Biologics	Vulvovaginal candidiasis	Vaccine		Phase 1/2	Women with recurrent vulvovaginal candidiasis	https://clinicaltrials.gov/study/NCT06190509?intr=Vaccine&aggFilters=status:not%20rec&rank=9
LiteVax BV	Pneumococcal	Vaccine		Phase 1	Adults 18-50 years of age	https://clinicaltrials.gov/study/NCT06986239?intr=Vaccine&aggFilters=status:not%20rec&page=51&rank=502
MAXVAX Biotechnology Limited Liability Company	RSV	Vaccine		Phase 3	Adults 60+ years old	https://clinicaltrials.gov/study/NCT07272434?intr=Vaccine&aggFilters=status:not%20rec&page=45&rank=441
Medigen	Venezuelan Equine Encephalitis	Vaccine	V4020	Phase 1	Adults	https://clinicaltrials.gov/study/NCT07088822?intr=Vaccine&aggFilters=status:not%20rec&page=61&rank=601
Medigen Vaccine Biologics Corp.	Enterovirus	Vaccine	Envacgen	Phase 3	Children 6-10 years of age	https://clinicaltrials.gov/study/NCT07178522?intr=Vaccine&aggFilters=status:not%20rec&page=54&rank=532
Merck	Dengue	Vaccine	V181	Phase 3	Children 2—17 regardless of	
Merck	Pneumococcal	Vaccine	V118C-002	Phase 1	children 12-15 months of age	https://clinicaltrials.gov/study/NCT07300267?intr=Vaccine&aggFilters=status:not%20rec&page=62&rank=611

Moderna	CMV	mRNA vaccine	mRNA-1647	Phase 2	Transplant recipients	Broader trials failed in Q3 2025	https://www.modernatx.com/en-US/research/product-pipeline
Moderna	EBV	mRNA vaccine	mRNA-1189	Phase 2		to prevent infectious mononucleosis	https://www.modernatx.com/en-US/research/product-pipeline
Moderna	EBV	mRNA vaccine	mRNA-1195	Phase 2		to address long term EBV sequelae	https://www.modernatx.com/en-US/research/product-pipeline
Moderna	HIV	mRNA vaccine	mRNA-1644	Phase 1			https://www.modernatx.com/en-US/research/product-pipeline
Moderna	Influenza	mRNA vaccine	mRNA-1010	Phase 3	Adults		https://www.modernatx.com/en-US/research/product-pipeline
Moderna	Lyme Disease	mRNA vaccine	mRNA-1975	Phase 2			https://www.modernatx.com/en-US/research/product-pipeline
Moderna	Lyme Disease	mRNA vaccine	mRNA-1982	Phase 2			https://www.modernatx.com/en-US/research/product-pipeline
Moderna	Mpox	mRNA vaccine	mRNA-1769	Phase 1			https://www.modernatx.com/en-US/research/product-pipeline
Moderna	Nipah	mRNA vaccine	mRNA-1215	Phase 1			https://www.modernatx.com/en-US/research/product-pipeline
Moderna	Norovirus vaccine	mRNA vaccine	mRNA-1403	Phase 3			https://www.modernatx.com/en-US/research/product-pipeline
Moderna	Norovirus vaccine	mRNA vaccine	mRNA-1405	Phase 3			https://www.modernatx.com/en-US/research/product-pipeline
Moderna	Pandemic influenza vaccine	mRNA vaccine	mRNA-1018	Phase 3	Adults	Received funding from CEPI after HHS cut fundin	https://www.modernatx.com/en-US/research/product-pipeline

Moderna	RSV	mRNA vaccine	mRNA-1345	Phase 2	Pediatrics		https://www.modernatx.com/en-US/research/product-pipeline
Moderna	RSV + hMPV	mRNA vaccine	mRNA-1365	Phase 2	Adults		https://www.modernatx.com/en-US/research/product-pipeline
Moderna	Flu + COVID	mRNA vaccine	mrRNA-1083	Phase 3	Adults		https://www.modernatx.com/en-US/research/product-pipeline
National Institute of Allergy and Infectious Diseases	COVID	Intranasal Vaccine	Boost-2867	Phase 1	Healthy adults		https://clinicaltrials.gov/study/NCT07221162?intr=Vaccine&aggFilters=status:not%20rec&page=66&rank=653
National Institute of Allergy and Infectious Diseases	Cytomegalovirus	Vaccine		Phase 2	Liver transplant candidates		https://clinicaltrials.gov/study/NCT06075745?intr=Vaccine&aggFilters=status:not%20rec&page=41&rank=403
National Institute of Allergy and Infectious Diseases	Epstein-Barr virus	Vaccine		Phase 1	Healthy EBV-negative or EBV-positive people aged 18 to 29		https://clinicaltrials.gov/study/NCT06908096?intr=Vaccine&aggFilters=status:not%20rec&page=37&rank=366
National Institute of Allergy and Infectious Diseases	HIV	Vaccine		Phase 1	Adults living with HIV on antiretroviral therapy	therapeutic vaccine	https://clinicaltrials.gov/study/NCT06680479?intr=Vaccine&aggFilters=status:not%20rec&page=37&rank=361
National Institute of Allergy and Infectious Diseases	HIV	Vaccine		Phase 1/2	Adults living with HIV on antiretroviral therapy	therapeutic vaccine	https://clinicaltrials.gov/study/NCT06071767?intr=Vaccine&aggFilters=status:not%20rec&page=39&rank=383#participation-criteria
National Vaccine and Serum Institute, China	HPV	Vaccine		Phase 3	Women aged 9-45 years old	11-valent	https://clinicaltrials.gov/study/NCT05262010?intr=Vaccine&aggFilters=status:not%20rec&page=45&rank=443

New York State Psychiatric Institute	Opioid use disorder	Vaccine	Oxy(Gly)4-sKLH	Phase 1/2	Healthy adults, aged 18 to 59 years, who meet DSM-5 criteria for OUD but are not seeking treatment for their drug use and are physically dependent on opioids	https://clinicaltrials.gov/study/NCT04458545?intr=Vaccine&aggFilters=status:not%20rec&page=23&rank=228
Ningbo Rongan Biological Pharmaceutical Co., Ltd.	Rabies	Vaccine		Phase 3	10-60 year olds	https://clinicaltrials.gov/study/NCT07028801?intr=Vaccine&aggFilters=status:not%20rec&page=32&rank=311
Novavax	Clostridioides difficile (C. difficile)	Vaccine		Pre-Clinical		https://www.novavax.com/products-pipeline/pipeline
Novavax	Combination COVID-19 and Influenza	Vaccine		Phase 3		https://www.novavax.com/products-pipeline/pipeline
Novavax	Pandemic influenza	Vaccine		Pre-Clinical		https://www.novavax.com/products-pipeline/pipeline
Novavax	RSV + hMPV	Vaccine		Pre-Clinical		https://www.novavax.com/products-pipeline/pipeline
Novavax	Seasonal influenza	Vaccine		Phase 3	Older adults	https://www.novavax.com/products-pipeline/pipeline
Novavax	Shingles	Vaccine		Pre-Clinical		https://www.novavax.com/products-pipeline/pipeline
Nuravax	Alzheimers	Vaccine		Phase 1	Healthy adults	https://clinicaltrials.gov/study/NCT07142278?intr=Vaccine&aggFilters=status:not%20rec&page=66&rank=651
PATH	Polio	Oral Vaccine		Phase 2	Children 1-5 years old	https://clinicaltrials.gov/study/NCT05654467?intr=Vaccine&aggFilters=status:not%20rec&page=35&rank=347

Peptinov SAS	Osteoarthritis	Vaccine	PPV-06	Phase 2	Adults with knee osteoarthritis		https://clinicaltrials.gov/study/NCT06605963?intr=Vaccine&aggFilters=status:not%20rec&page=49&rank=483
							https://clinicaltrials.gov/study/NCT07282665
Pfizer	Clostridioides difficile (C. difficile)	Vaccine	PF-07831694	Phase 3	65+ years old	Updated formulation	https://mednews.uw.edu/news/vaccine-trial-cdiff
Pfizer	Combination COVID-19 and Influenza	mRNA vaccine	PF-07926307	Phase 2		in collaboration with BioNTech	https://www.pfizer.com/science/drug-product-pipeline
Pfizer	COVID-19	mRNA vaccine		Phase 3	6 months-11 years of age	Product Enhancement	https://www.pfizer.com/science/drug-product-pipeline
Pfizer	E coli	Vaccine		Phase 1	healthy adults		https://clinicaltrials.gov/study/NCT07122986?intr=Vaccine&aggFilters=status:not%20rec&page=13&rank=127
Pfizer	Influenza	mRNA vaccine	PF-07252220	Phase 2	Adults		https://www.pfizer.com/science/drug-product-pipeline
Pfizer	Invasive Group B Streptococcus Infection	Vaccine	PF-06760805	Phase 3	maternal	Breakthrough fast track	https://www.pfizer.com/science/drug-product-pipeline
							https://www.pfizer.com/science/drug-product-pipeline
Pfizer	Lyme Disease	Vaccine	PF-07307405	Phase 3		Fast Track	Phase 3 trial did not meet primary endpoint in March 2026, but Pfizer to still seek FDA approval
Pfizer	Pandemic influenza	mRNA vaccine	PF-07985819	Phase 1			https://www.pfizer.com/science/drug-product-pipeline
Pfizer	Pneumococcal Infection	Vaccine	PF-07872412	Phase 2		Fast Track	https://www.pfizer.com/science/drug-product-pipeline

Pfizer	RSV	Vaccine			pediatric	Product Enhancement	https://www.pfizer.com/science/drug-product-pipeline
							https://clinicaltrials.gov/study/NCT05703607?intr=Vaccine&aggFilters=status:not%20rec&page=47&rank=462
Pfizer	Shingles	mRNA vaccine		Phase 2	Adults 50-85 years old		https://www.pfizer.com/science/drug-product-pipeline
Pfizer	Influenza	mRNA vaccine	PF-07845104	Phase 1			https://clinicaltrials.gov/study/NCT06837116?intr=Vaccine&aggFilters=status:not%20rec&page=2&rank=20
Prince of Songkla University	Dengue	Vaccine		Early Phase 1	healthy adults		https://clinicaltrials.gov/study/NCT06803342?intr=Vaccine&aggFilters=status:not%20rec&page=15&rank=141
Sabin Institute	Ebola	Vaccine		Phase 2	healthy adults up to 70 years old		https://www.sanofi.com/en/our-science/our-pipeline
							https://clinicaltrials.gov/study/NCT06316297?intr=Vaccine&aggFilters=status:not%20rec&page=21&rank=210
Sanofi	Acne	mRNA vaccine	SP0268	Phase 2			https://www.sanofi.com/en/our-science/our-pipeline
Sanofi	Chlamydia	mRNA vaccine	SP0269	Phase 1			https://www.sanofi.com/en/our-science/our-pipeline
Sanofi	Flu + COVID	Vaccine	SP0287	Phase 1		Flubok + Nuvaxovid	https://www.sanofi.com/en/our-science/our-pipeline
Sanofi	Flu + COVID	Vaccine	SPO291	Phase 1		Fluzone HD + Nuvaxovid	https://www.sanofi.com/en/our-science/our-pipeline
Sanofi	H5 Pandemic Influenza	Vaccine	SP0335	Phase 2		inactivated adjuvanted	https://www.sanofi.com/en/our-science/our-pipeline
Sanofi	Influenza	mRNA vaccine	SP0237	Phase 1			https://www.sanofi.com/en/our-science/our-pipeline

Sanofi	Influenza	Vaccine	Fluzone HD	Phase 3	50+ year olds	multivalent inactivated	https://www.sanofi.com/en/our-science/our-pipeline
Sanofi	meningitis	Vaccine	SP0230	Phase 2		5-valent ACYW+B	https://www.sanofi.com/en/our-science/our-pipeline https://clinicaltrials.gov/study/NCT06647407?intr=Vaccine&aggFilters=status:not%20rec&page=4&rank=32
Sanofi	Pneumococcal	Vaccine	SP0202	Phase 3		21 valent	https://www.sanofi.com/en/our-science/our-pipeline https://clinicaltrials.gov/study/NCT06975878?intr=Vaccine&aggFilters=status:not%20rec&page=2&rank=17
Sanofi	Rabies	Vaccine	SP0087	Phase 3		vero cell	https://www.sanofi.com/en/our-science/our-pipeline
Sanofi	RSV	mRNA vaccine	SP0256	Phase 2	Older adults		https://www.sanofi.com/en/our-science/our-pipeline
Sanofi	RSV + hMPV	mRNA vaccine	SP0256	Phase 1	Older adults		https://www.sanofi.com/en/our-science/our-pipeline
Sanofi	RSV + hMPV + PIV3	mRNA vaccine	SP0291	Phase 1	Older adults		https://www.sanofi.com/en/our-science/our-pipeline https://clinicaltrials.gov/study/NCT07103148?intr=Vaccine&aggFilters=status:not%20rec&page=4&rank=37
Sanofi	Yellow Fever	Vaccine	SP0218	Phase 3			https://www.sanofi.com/en/our-science/our-pipeline
Sanofi	H5 Pandemic Influenza	mRNA vaccine	SP0289	Phase 2			https://www.sanofi.com/en/our-science/our-pipeline

Serum Institute of India Pvt. Ltd.	Polio	Vaccine	Phase 3	Infants 6-8 weeks	SIPL has manufactured hexavalent combination vaccine containing diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and a reduced dose of three IPV antigens.	https://clinicaltrials.gov/study/NCT06413121?intr=Vaccine&aggFilters=status:not%20rec&page=40&rank=397
Shanghai Bovax Biotechnology Co., Ltd.	HPV	Vaccine	Phase 2	9-45 year olds	15-valent	https://clinicaltrials.gov/study/NCT06756269?intr=Vaccine&aggFilters=status:not%20rec&page=17&rank=167
Shanghai Institute Of Biological Products	Mpox	Vaccine	Phase 1	18 years and older		https://clinicaltrials.gov/study/NCT06771479?intr=Vaccine&aggFilters=status:not%20rec&page=35&rank=344#participation-criteria
Sinocelltech Ltd	Herpes Zoster	Vaccine	Phase 1/2	Adults 40+ years old		https://clinicaltrials.gov/study/NCT06801509?intr=Vaccine&aggFilters=status:not%20rec&page=42&rank=418
Sinovac Biotech Co., Ltd	Enterovirus	Vaccine	Phase 1/2	Children 6 months-12 years		https://clinicaltrials.gov/study/NCT06754384?intr=Vaccine&aggFilters=status:not%20rec&page=38&rank=377
Sinovac Biotech Co., Ltd	Influenza	Vaccine	Phase 3	Pregnant women		https://clinicaltrials.gov/study/NCT07211152?intr=Vaccine&aggFilters=status:not%20rec&page=42&rank=416
Sinovac Biotech Co., Ltd	Pneumococcal	Vaccine	Phase 1	Infants 2 months-23 months	23-valent	https://clinicaltrials.gov/study/NCT06800261?intr=Vaccine&aggFilters=status:not%20rec&page=68&rank=671

Sinovac Biotech Co., Ltd	Rabies	Vaccine		Phase 3	participants greater than 1 year of age	Pre-exposure prophylaxis	https://clinicaltrials.gov/study/NCT07055295?intr=Vaccine&aggFilters=status:not%20rec&page=37&rank=367
Sinovac Life Sciences Co., Ltd.	Rotavirus	Vaccine		Phase 2	Infants 6-12 weeks		https://clinicaltrials.gov/study/NCT06967272?intr=Vaccine&aggFilters=status:not%20rec&page=28&rank=274
SK Bioscience Co. Ltd	Sarbecovirus	Vaccine	GBP511	Phase 1/2	Healthy adults		https://clinicaltrials.gov/study/NCT07280858?intr=Vaccine&aggFilters=status:not%20rec&page=67&rank=665
Statens Serum Institut	Tuberculosis	Vaccine		Phase 1	Adults		https://clinicaltrials.gov/study/NCT06050356?intr=Vaccine&aggFilters=status:not%20rec&page=64&rank=638
Takeda	Dengue	Vaccine		Phase 3	Adults aged 18-60 years old		https://clinicaltrials.gov/study/NCT07047521?intr=Vaccine&aggFilters=status:not%20rec&page=13&rank=123
Tsinghua University	Influenza	oral tablet		N/A	adults aged 60-70 years of age	This study will conduct a randomized clinical trial to compare the efficacy of fatty acid / bile acid (Tauro Ursodesoxy Cholic Acid, TUDCA) supplements on enhancing vaccine immune response	https://clinicaltrials.gov/study/NCT06827873?intr=Vaccine&aggFilters=status:not%20rec&page=38&rank=371
U.S. Army Medical Research and Development Command	Rift Valley Fever Vaccine	Vaccine		Phase 2	18-65 year old adults		https://clinicaltrials.gov/study/NCT03609398?intr=Vaccine&aggFilters=status:not%20rec&page=7&rank=69#participation-criteria

University of Alabama at Birmingham	Pneumococcal	Vaccine		Phase 4	healthy adults	33-valent	https://clinicaltrials.gov/study/NCT07135453?intr=Vaccine&aggFilters=status:not%20rec&page=5&rank=47#participation-criteria
University of Alberta	Hepatitis C	Vaccine		Phase 1	adults aged 18-65 years		https://clinicaltrials.gov/study/NCT07237282?intr=Vaccine&aggFilters=status:not%20rec&page=38&rank=375#participation-criteria
University of Maryland Baltimore	Chronic Hepatitis B	Vaccine	HEPLISAV-B	Phase 1	Adults living with chronic hepatitis B		https://clinicaltrials.gov/study/NCT04843852?intr=Vaccine&aggFilters=status:not%20rec&page=46&rank=457#participation-criteria
University of Maryland Baltimore	Salmonella	Vaccine		Phase 2	Adults, children 5-9, children 24-59 months, children 15-23 months of age		https://clinicaltrials.gov/study/NCT05784701?intr=Vaccine&aggFilters=status:not%20rec&page=39&rank=390

University of North Carolina Chapel Hill	Neisseria Gonorrhoeae	Vaccine	Bexero	Phase 2	males 18-36 years old	<p>randomized controlled trial to test whether the group B meningitis vaccine 4 component Neisseria meningitidis serogroup B vaccine (BEXSEROTM) (4C-MenB), trade name Bexsero™), currently approved for use by the United States Food and Drug Administration (FDA) and recommended by the Centers for Disease Control and Prevention (CDC) for protection from Neisseria meningitidis infections, also protects from Neisseria gonorrhoeae infection using controlled human experimental infection to test protection. The information the investigator learn by doing this study may also</p> <p>https://clinicaltrials.gov/study/NCT05294588?intr=Vaccine&aggFilters=status:not%20rec&page=17&rank=161</p>
University of Oxford	Malaria	Vaccine	PvRII/Matrix-M	Phase 2	healthy adults	<p>https://clinicaltrials.gov/study/NCT05380388?intr=Vaccine&aggFilters=status:not%20rec&page=2&rank=16</p>
University of Oxford	Malaria	Vaccine		Phase 2	Infants aged 5-17 months	<p>https://clinicaltrials.gov/study/NCT05790889?intr=Vaccine&aggFilters=status:not%20rec&page=37&rank=365</p>
University of Oxford	Malaria	Vaccine		Phase 2	Children aged 5-36 months	<p>https://clinicaltrials.gov/study/NCT07183371?intr=Vaccine&aggFilters=status:not%20rec&page=41&rank=407</p>

University of Oxford	Rabies	Vaccine	ChAdOx2 RabG	Phase 2	Adults 18-45 years old		https://clinicaltrials.gov/study/NCT07168018?intr=Vaccine&aggFilters=status:not%20rec&page=29&rank=288#participation-criteria
Valneva	Lyme Disease	Vaccine	VLA15	Phase 3		Partnership with Pfizer; see details above	https://valneva.com/research-development/
Vaxcyte, Inc.	Pneumococcal	Vaccine		Phase 3	Adults older than 50	31-valent	https://clinicaltrials.gov/study/NCT07284654?intr=Vaccine&aggFilters=status:not%20rec&page=39&rank=387
Vaxine Pty Ltd	COVID-19 and Influenza	Oral Vaccine	Vaxine-2301	Phase 1	adults 18+ years old		https://clinicaltrials.gov/study/NCT06355232?intr=Vaccine&aggFilters=status:not%20rec&page=2&rank=11
Vicebio Australia Proprietary Limited	RSV + hMPV-PIV3	Vaccine	VXB-251	Phase 1	Older adults		https://clinicaltrials.gov/study/NCT07295028?intr=Vaccine&aggFilters=status:not%20rec&page=40&rank=399
Virometix AG	Pneumococcal	Vaccine	V-212	Phase 1	18-45 year olds		https://www.businesswire.com/news/home/20260108510147/en/Virometix-AG-Announces-Positive-Data-from-Phase-1-Trial-of-V-212-a-Fully-Synthetic-Serotype-Independent-Vaccine-Development-Candidate-for-the-Prevention-of-Pneumococcal-Disease
University of Oxford	Filoviruses	Vaccine				Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus; Funded by CEPI	https://cepi.net/ambitious-research-aims-develop-multivalent-vaccines-protect-against-multiple-deadly-filoviruses

IAVI	HIV	mRNA vaccine	IAVI G0004	Phase 1			https://www.iavi.org/press-release/iavi-announces-first-vaccinations-in-iavi-g004-a-phase-1-clinical-trial-of-a-promising-hiv-vaccine-approach/
Mass General Brigham Hospital	Chlorea	Vaccine	PanChol	Phase 1	healthy adults	Phase 1 is complete	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00682-6/fulltext https://www.cidrap.umn.edu/cholera/novel-cholera-vaccine-shows-promise-phase-1-trial
University of Oxford and Serum Institute	Rift Valley Fever Vaccine	Vaccine		Investigational	outbreak-affected areas	Funding by CEPI	https://www.cidrap.umn.edu/rift-valley-fever/cepi-announces-funding-rift-valley-fever-vaccine https://cepi.net/cepi-oxford-serum-create-largest-ever-reserve-investigational-rift-valley-fever-vaccine
Indian Council of Medical Research	Tuberculosis	Vaccine	VMP1002 and Immuvac	Phase 3	Participants aged 6-14 years of age		https://www.bmj.com/content/393/bmj-2025-085716